3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
2
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Cyclophosphamide
345
Rituximab
309
Vincristine
160
Doxorubicin
157
venetoclax
156
fludarabine
153
Specimen Handling
152
Prednisone
152
Biopsy
122
obinutuzumab
117
Magnetic Resonance Spectroscopy
117
Lenalidomide
110
Dexamethasone
106
Cytarabine
100
ibrutinib
96
Etoposide
94
fludarabine phosphate
87
Methotrexate
86
acalabrutinib
79
zanubrutinib
73
Bendamustine Hydrochloride
73
pembrolizumab
63
blinatumomab
63
CT-P10
61
Gemcitabine
52
glofitamab
45
Nivolumab
45
Calcium Dobesilate
45
Mercaptopurine
44
prednylidene
43
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hizentra
×
Lymphoid
×
1 year
×
Clear all
NCT07582432
2026-05-12
SIGMA
Grifols Biologicals, LLC
Phase 3
Recruiting
49 enrolled